<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01927029</url>
  </required_header>
  <id_info>
    <org_study_id>CAS149</org_study_id>
    <nct_id>NCT01927029</nct_id>
  </id_info>
  <brief_title>Preterm Delivery Prevention in Twins With Progesterone</brief_title>
  <official_title>Prevenci√≥n de Parto Prematuro en Gemelares: Ensayo Aleatorio Con Progesterona Vaginal.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad del Desarrollo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Padre Hurtado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital San Borja-Arriaran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad del Desarrollo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Twin pregnancies have very high preterm delivery rate. Until now, no RCT has proven benefit
      of progesterone in this population. In contrast, singleton pregnancies are treated with this
      hormone. The objective is to compare 180mg/day progeterone vaginal gel with 180mg/day with
      placebo, from 18 weeks to 34 weeks. The sample size was calculated and 213 cases in each
      group are needed to demonstrate a reduction of preterm delivery &lt;34weeks from 13% to 7%.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preterm delivery &lt;34 weeks</measure>
    <time_frame>14 months</time_frame>
    <description>Spontaneous labor under 34 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preterm delivery &lt;37 weeks</measure>
    <time_frame>14 months</time_frame>
    <description>Spontaneous delivery under 37 weeks</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Neonatal mortality</measure>
    <time_frame>14 months</time_frame>
    <description>Dead of the newborn, due to preterm delivery</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">213</enrollment>
  <condition>Pregnancies</condition>
  <arm_group>
    <arm_group_label>Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily administration of vaginal progesterone, 180mg, in gel, from 18 weeks to 34 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Gel, for daily use from 18 weeks to 34 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Vaginal progesterone gel 180mg/daily is given from second trimester (18 to 24 weeks) until 34 weeks.</description>
    <arm_group_label>Progesterone</arm_group_label>
    <other_name>Progendo gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Monochorionic or Dichorionic twin pregnancies

          -  18 weeks to 24 weeks at inclusion.

        Exclusion Criteria:

          -  Cerclage before inclusion

          -  Contractions, rupture of the membranes, cervix dilation,

          -  Short cervix (15mm or 20mm if there is history of preterm delivery

          -  Monoamniotic twins, Major malformation, Selective IUGR, TRAP, TTTS.

          -  Younger than 14 years.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2013</study_first_submitted>
  <study_first_submitted_qc>August 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2013</study_first_posted>
  <last_update_submitted>August 20, 2013</last_update_submitted>
  <last_update_submitted_qc>August 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinica Alemana de Santiago</investigator_affiliation>
    <investigator_full_name>Masami Yamamoto</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>twin pregnancy</keyword>
  <keyword>progesterone</keyword>
  <keyword>preterm delivery</keyword>
  <keyword>&gt;14 years</keyword>
  <keyword>Abscense of cerclage,</keyword>
  <keyword>TTTS, hemorrage,</keyword>
  <keyword>history of thrombosis.</keyword>
  <keyword>cervix &gt;15mm</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

